Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in NMOSD
NCT04201262Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of ravulizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Alexion Pharmaceuticals. Started Dec 2019; status: completed.
02
Drugs
ravulizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT04201262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04201262.